NextCure, Inc. (NXTC)
5.34
+0.52
(+10.79%)
USD |
NASDAQ |
Sep 24, 16:00
5.34
0.00 (0.00%)
After-Hours: 19:59
NextCure Enterprise Value : 3.812M for Sept. 23, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 23, 2026 | 3.812M |
| September 22, 2026 | 5.276M |
| September 21, 2026 | 6.416M |
| September 18, 2026 | 9.101M |
| September 17, 2026 | 7.270M |
| September 16, 2026 | 8.735M |
| September 15, 2026 | 10.12M |
| September 14, 2026 | 11.22M |
| September 11, 2026 | 12.68M |
| September 10, 2026 | 13.94M |
| September 09, 2026 | 17.04M |
| September 08, 2026 | 18.46M |
| September 04, 2026 | 16.02M |
| September 03, 2026 | 16.10M |
| September 02, 2026 | 14.11M |
| September 01, 2026 | 11.87M |
| August 31, 2026 | 10.20M |
| August 28, 2026 | 8.979M |
| August 27, 2026 | 8.755M |
| August 26, 2026 | 7.921M |
| August 25, 2026 | 8.247M |
| August 24, 2026 | 8.165M |
| August 21, 2026 | 9.793M |
| August 20, 2026 | 9.630M |
| August 19, 2026 | 11.79M |
| Date | Value |
|---|---|
| August 18, 2026 | 11.26M |
| August 17, 2026 | 15.57M |
| August 14, 2026 | 17.61M |
| August 13, 2026 | 17.89M |
| August 12, 2026 | 17.44M |
| August 11, 2026 | 11.58M |
| August 10, 2026 | 12.03M |
| August 07, 2026 | 7.962M |
| August 06, 2026 | 6.945M |
| August 05, 2026 | 5.561M |
| August 04, 2026 | 7.718M |
| August 03, 2026 | 2.103M |
| July 31, 2026 | 1.065M |
| July 30, 2026 | 4.666M |
| July 29, 2026 | 4.625M |
| July 28, 2026 | 6.253M |
| July 27, 2026 | 5.032M |
| July 24, 2026 | 1.452M |
| July 23, 2026 | 1.207M |
| July 22, 2026 | 2.103M |
| July 21, 2026 | 4.992M |
| July 20, 2026 | 6.172M |
| July 17, 2026 | 8.572M |
| July 16, 2026 | 9.305M |
| July 15, 2026 | 11.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.225B |
| Oncolytics Biotech, Inc. | 80.65M |
| Sangamo Therapeutics, Inc. | 53.31M |
| Sarepta Therapeutics, Inc. | 2.259B |
| Anixa Biosciences, Inc. | 80.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.89M |
| Total Expenses (Quarterly) | 14.89M |
| EPS Diluted (Quarterly) | -2.805 |
| Earnings Yield | -198.3% |
| Normalized Earnings Yield | -185.75 |